VOLUNTARY IMPROVEMENT PROGRAM (VIP)

A Program of the Case for Quality Collaborative Community (CfQcc)

FDA and industry seek to move medical device manufacturing from a culture of compliance to a culture of quality. While this desire to improve device quality and safety is a motivating factor for the ecosystem, there is little information available about (1) how a device manufacturer can consistently demonstrate and evaluate quality and (2) if and how FDA would recognize and reward quality within an organization. Defining a path for manufacturers to improve quality and demonstrating how doing so could reduce regulatory burden could help bring about the shift to a culture of quality.

CfQcc Voluntary Improvement Program (VIP)

The VIP emphasizes consistent quality manufacturing alongside compliance to advance device quality and safety. Device manufacturers who are committed to quality undergo a quality appraisal to assess their capability to manufacture high-quality devices, including current strengths and areas of improvement. Recognizing participants’ commitment to quality and leveraging the performance appraisal information, FDA can simplify regulatory requirements, reducing associated burden for medical device manufacturers.

A pilot version of VIP launched in 2018. More than 80% of the program participants report that the appraisal benefited product quality and more than 90% report a positive experience. Participants have seen hundreds of thousands of dollars in operational improvements as well as millions of dollars in revenue opportunities. VIP is transitioning from pilot to program and is expected to be fully operational in FY 2021.

RESOURCES
VIP Results Report:

FDA’s VIP Web Page:

VIP Application:
https://mdic.org/project/cdrh-quality-pilot/

CASE FOR QUALITY COLLABORATIVE COMMUNITY (CfQcc)

The VIP is an effort of the Case for Quality Collaborative Community (CfQcc). CfQcc offers a unique forum for medical device stakeholders to move beyond baseline regulatory compliance activities and collaboratively develop sustained predictive practices that advance medical device quality and safety to achieve better patient outcomes.

Collaborative Communities provide a forum for public and private sector members to proactively work together to achieve common objectives and outcomes. FDA does not lead Collaborative Communities, and their work does not replace established regulatory mechanisms. However, FDA may choose to participate in a Collaborative Community and support, leverage, and/or adopt solutions that emerge.

GET INVOLVED WITH THE VIP TODAY!

Contact Alan Baumel, Program Director for CfQcc, at abaumel@mdic.org.
Apply to the VIP at https://mdic.org/project/cdrh-quality-pilot/
About MDIC
The Medical Device Innovation Consortium (MDIC) is a public-private partnership that brings together representatives of the FDA, NIH, CMS, industry, nonprofits, and patient organizations to improve the processes for development, assessment, and review of new medical technologies. We are working toward faster, safer, and more cost-effective innovation for patient benefit.

MDIC has been formed to add value at the intersecting needs of the medical device industry, the FDA, and the related organizations that are together responsible for a vibrant medical device industry that serves the public health needs of the United States.

Vision
MDIC, through its public-private partnership, aims to advance regulatory science in the medical device industry. MDIC will coordinate the development of methods, tools, and resources used in managing the total product life cycle of a medical device to improve patient access to cutting-edge medical technology.

Initiatives and Programs
MDIC’s initiatives focus on four areas, each of which has one or more programs to meet a specific need:

1. Clinical Science – Addresses the biggest barriers to collecting adequate clinical evidence in the support of new medical technology by creating blueprints for innovative clinical trials techniques, developing standards and metrics for effective clinical trial designs, and encouraging the collection of adequate and appropriate clinical and patient preference data
   • Clinical Diagnostics
   • Early Feasibility Studies
   • Science of Patient Input

2. Data Science & Technology – Fulfills the promise of advances in data analysis by creating tools and methods to use advanced data analysis techniques and new technology to accelerate the collection of clinical data, remove barriers to patient access, and monitor product safety, quality, and effectiveness
   • Case for Quality Collaborative Community
   • Computational Modeling and Simulation
   • Cybersecurity
   • External Evidence Methods
   • Systemic Harmonization and Interoperability Enhancement for Lab Data (SHIELD)
   • 5G-Enabled Health Technologies

3. Health Economics & Patient Value – Creates predictability and transparency of evidentiary requirements for coverage and improves pathways for coverage, coding, and payment to speed patient access and amplify the patient voice in selection of treatment options

4. National Evaluation System for Health Technology Coordinating Center (NESTcc) – Works with stakeholders across the medical device ecosystem to catalyze the timely, reliable, and cost-effective development of Real-World Evidence to enhance regulatory and clinical decision-making.

LEARN MORE ABOUT MDIC
Learn more about MDIC by visiting www.mdic.org, sending a message to info@mdic.org, or calling (202) 828-1600.

MDICx Series
MDIC’s informative series of online workshops, the MDICx series, features emerging trends in medical technology, regulatory science, MDIC projects, and subject matter experts sharing perspectives, progress, and opportunities. Visit mdic.org/mdicx-series to view upcoming webinars or submit a proposal.

ANNUAL PUBLIC FORUM
Every year, MDIC’s Annual Public Forum (APF) brings together MDIC members and the broader medical device and diagnostics community to share insights on current trends in regulatory science and the progress MDIC has made in advancing the field. Learn more at https://apf.mdic.org/agenda/

Past panel topics have included:
• Developing a patient-centered regulatory strategy
• Assessing the Use, Impact, and Role of RWE in the U.S. and EU
• Mitigating cybersecurity risks to ensure device security and patient safety

Past guest speakers have included:
• FDA Commissioners Hahn, Gottlieb, and Califf; Acting Commissioner Sharpless
• Tamara Syrek Jensen, Director of the Coverage and Analysis Group, CMS
• Danelle Miller, Vice President, Global Regulatory Policy & Intelligence - Roche Diagnostics

MEMBERSHIP
MDIC members are leaders in the medical technology industry. MDIC focuses on providing patients access to innovative medical technologies, so many of our members are companies that can help us serve this mission. Member organizations are substantially involved in medical and/or medical device research, development, treatment, or education; the promotion of public health; or expertise in regulatory science.

MDIC COLLABORATORS